What next after basal insulin? Treatment intensification with lixisenatide in Asian patients with type 2 diabetes mellitus-Reference-Cited by-同舟云学术

What next after basal insulin? Treatment intensification with lixisenatide in Asian patients with type 2 diabetes mellitus

Published:2017-01-23 Issue:6 Volume:9 Page:562-574
ISSN:1753-0393
Container-title:Journal of Diabetes
language:en
Short-container-title:Journal of Diabetes

Author:

Chan Wing B.¹,Luk Andrea²,Chow Wing S.³,Yeung Vincent T.F.⁴

Affiliation:

1. Endocrinology, Diabetes & Metabolism; Qualigenics Diabetes Centre; Hong Kong SAR China

2. Department of Medicine and Therapeutics; Chinese University of Hong Kong, Prince of Wales Hospital; Hong Kong SAR China

3. Department of Medicine; The University of Hong Kong, Queen Mary Hospital; Hong Kong SAR China

4. Department of Medicine and Geriatrics; Our Lady of Maryknoll Hospital; Hong Kong SAR China

Funder

Sanofi

Publisher

Wiley

Subject

Endocrinology, Diabetes and Metabolism

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/1753-0407.12515/fullpdf

Reference77 articles.

1. Management of hyperglycaemia in type 2 diabetes, 2015: A patient-centred approach. Update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes;Inzucchi;Diabetologia,2015

2. Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: Variations with increasing levels of HbA(1c);Monnier;Diabetes Care,2003

3. Contributions of basal and postprandial hyperglycemia over a wide range of A1C levels before and after treatment intensification in type 2 diabetes;Riddle;Diabetes Care,2011

4. Euglycemic diabetic ketoacidosis: A potential complication of treatment with sodium-glucose cotransporter 2 inhibition;Peters;Diabetes Care,2015

5. US Food and Drug Administration (FDA) FDA Drug Safety Communication: FDA Warns that SGLT2 Inhibitors for Diabetes May Result in A Serious Condition of Too Much Acid in the Blood 2015 http://www.fda.gov/Drugs/DrugSafety/ucm446845.htm

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Simultaneous Versus Sequential Initiation of Lixisenatide and Basal Insulin for Type 2 Diabetes: Subgroup Analysis of a Japanese Post-Marketing Surveillance Study of Lixisenatide (PRANDIAL);Advances in Therapy;2022-10-07

2. The Durable Safety and Effectiveness of Lixisenatide in Japanese People with Type 2 Diabetes: The Post-Marketing Surveillance PRANDIAL Study;Advances in Therapy;2022-04-21